Literature DB >> 3019968

Human pharmacokinetics of WR-2721.

L M Shaw, A T Turrisi, D J Glover, H S Bonner, A L Norfleet, C Weiler, M M Kligerman.   

Abstract

The pharmacokinetic properties of WR-2721 were investigated in 13 cancer patients given a 150 mg/M2 intravenous bolus dose of the drug. An average plasma clearance value of 2.17 L/min was obtained. Very little of the drug or the two metabolites, WR-1065 and WR-33278, were excreted in urine obtained after the blood collection schedule. Plasma concentrations of WR-2721 decreased by 94% within 6 minutes of drug administration. The mean value of 6.44 L obtained for the steady-state volume of distribution indicates that the extravascular space occupied by the drug is small. These observations suggest that in human cancer patients, WR-2721 is rapidly taken up by tissues and converted to metabolites.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3019968     DOI： 10.1016/0360-3016(86)90203-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


  14 in total

1.  A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy.

Authors:  Mary Feng; David E Smith; Daniel P Normolle; James A Knol; Charlie C Pan; Edgar Ben-Josef; Zheng Lu; Meihua R Feng; Jun Chen; William Ensminger; Theodore S Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-21       Impact factor: 7.038

Review 2.  A risk-benefit assessment of amifostine in cytoprotection.

Authors:  M Mabro; S Faivre; E Raymond
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 3.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Oxidative stress, redox regulation and diseases of cellular differentiation.

Authors:  Zhi-Wei Ye; Jie Zhang; Danyelle M Townsend; Kenneth D Tew
Journal:  Biochim Biophys Acta       Date:  2014-11-15

5.  Radioiodine-induced kidney damage and protective effect of amifostine: An experimental study.

Authors:  T Aktoz; G Durmus-Altun; U Usta; N Torun; A Ergulen; I H Atakan
Journal:  Hippokratia       Date:  2012-01       Impact factor: 0.471

Review 6.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

7.  Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.

Authors:  Trevor McKibbin; John C Panetta; Maryam Fouladi; Amar Gajjar; Feng Bai; M Fatih Okcu; Clinton F Stewart
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

Review 8.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

9.  p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection.

Authors:  E J Lee; M Gerhold; M W Palmer; R D Christen
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

10.  Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.

Authors:  D C Betticher; H Anderson; M Ranson; K Meely; W Oster; N Thatcher
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.